Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis

Series C financing led by NEA, joined by new investor Foresite Capital and Abcuro’s existing investors Proceeds to support completion of the registrational Phase 2/3 MUSCLE trial of ulviprubart in inclusion body myositis, BLA filing, and commercial launch preparation Newton, Massachusetts, February 12, 2025 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for READ MORE The post Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis appeared first on Abcuro .